scholarly journals Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study

Author(s):  
İlkay Anaklı ◽  
Perihan Ergin Özcan ◽  
Özlem Polat ◽  
Günseli Orhun ◽  
Gülçin Hilal Alay ◽  
...  
2019 ◽  
Vol 161 (9) ◽  
pp. 1943-1953 ◽  
Author(s):  
Ryuta Nakae ◽  
Shoji Yokobori ◽  
Yasuhiro Takayama ◽  
Takahiro Kanaya ◽  
Yu Fujiki ◽  
...  

2019 ◽  
Vol 22 (8) ◽  
pp. 696-704
Author(s):  
Elizabeth T Mansi ◽  
Jennifer E Waldrop ◽  
Elizabeth B Davidow

Objectives The goals of this study were to classify the indications, risks, effects on coagulation times and outcomes of cats receiving fresh frozen plasma (FFP) transfusions in clinical practice. Methods This was a retrospective study of FFP transfusions administered in two referral hospitals from 2014 to 2018. Transfusion administration forms and medical records were reviewed. Information was collected on indication, underlying condition, coagulation times and signs of transfusion reactions. Seven-day outcomes after FFP administration were also evaluated when available. Results Thirty-six cats received 54 FFP transfusions. Ninety-four percent of cats were administered FFP for treatment of a coagulopathy. Twenty cats had paired coagulation testing before and after FFP administration. Eighteen of these cats had improved coagulation times after receiving 1–3 units of FFP. Eight of the 36 cats had probable transfusion reactions (14.8% of 54 FFP transfusions). These reactions included respiratory signs (n = 4), fever (n = 2) and gastrointestinal signs (n = 2). Five of the eight cats with probable reactions had received packed red blood cells contemporaneously. Overall mortality rate during hospitalization was 29.7%, with 52.8% (n = 19/36) of cats confirmed to be alive 7 days after discharge. Conclusions and relevance This retrospective study shows that FFP transfusions improve coagulation times in cats. Transfusion reactions are a risk, and risk–benefit ratios must be measured prior to administration and possible reactions monitored. In the study cats, the FFP transfusions appeared to be a tolerable risk given the benefit to prolonged coagulation times.


Cornea ◽  
2008 ◽  
Vol 27 (4) ◽  
pp. 501-503 ◽  
Author(s):  
Vuslat Pelitli Gürlü ◽  
Muzaffer Demir ◽  
M Levent Alimgil ◽  
Sait Erda

2016 ◽  
Vol 38 (2) ◽  
pp. 357-360 ◽  
Author(s):  
L. Poli ◽  
A. Alberici ◽  
P. Buzzi ◽  
E. Marchina ◽  
A. Lanari ◽  
...  

Cornea ◽  
2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Selma Ozbek-Uzman ◽  
Zuleyha Yalniz-Akkaya ◽  
Burcu Nurozler Tabakci ◽  
Evin Singar ◽  
Ayse Burcu

Author(s):  
S. Nagulan ◽  
A. Hariharan ◽  
I. Sureshkumar ◽  
S. Chitra

Aim: To study the efficacy of Fresh Frozen Plasma (FFP) transfusion practice in patients with coagulation abnormalities varies in clinical practice. Study Design: A retrospective study. Place and Duration of Study: This study was conducted in Department of Transfusion Medicine, SMCH, Chennai, between the period of 2019-2020. Methodology: The medical records of each patient receiving FFP transfusions that occurred in patients with coagulation abnormalities were reviewed and the data were collected based on pre-and post transfusion PT (>12 sec), APTT (>70sec) and INR (>1.5) and then analysed statistically. Patients with normal coagulation parameters were excluded from study. Results: A total of 1259 units of fresh frozen plasma were transfused to 315 patients between the year 2019-2020. Of the 1259 units transfused 1133 units where transfused to 283 patients with coagulation abnormalities. Apparently 32 patients were excluded from the study as they had normal coagulation profile. Among 251 patients, 37 patients PT were greater than 12 seconds before FFP transfusion out of which the PT was corrected for 14 patients (37.8%) after FFP transfusion. In 228 patients APTT was greater than 70 seconds before FFP transfusion, out of which APTT was corrected in 18 patients (8%) after transfusion. INR values for all 251 patients were greater than1.5 before FFP transfusion, out of which INR was corrected in 84 patients (29%) after transfusion. Conclusion: We conclude that FFP transfusions in patients with coagulation abnormalities maycorrects the defect only in less percentage of patient population, as in our study it corrects only an average of 31% of patient population.


Sign in / Sign up

Export Citation Format

Share Document